Portal de Periódicos da CAPES

Dermatomyositis Which Was Double Positive for Anti-MDA5 and Anti-ARS Antibodies That Was Successfully Treated by Intensive Immunosuppressive Therapy

2022; The Japanese Society of Internal Medicine; Volume: 61; Issue: 7 Linguagem: Inglês

10.2169/internalmedicine.8579-21

1349-7235

Satoshi Hama, Misako Higashida‐Konishi, Mitsuhiro Akiyama, Tatsuya Shimada, Hiroshi Takei, Keisuke Izumi, Hisaji Oshima, Yutaka Okano,

Immunodeficiency and Autoimmune Disorders

Myositis-specific autoantibody is associated with the clinical phenotype and prognosis of dermatomyositis. Anti-melanoma differentiation-associated gene 5 (MDA5) and anti-aminoacyl-tRNA synthetase (ARS) antibodies are generally mutually exclusive. We herein present an extremely rare case of dermatomyositis which showed double positivity for anti-MDA5 and anti-ARS antibodies. There have been very few reported cases of double positive anti-MDA5, anti-ARS antibodies. In such cases, the clinical characteristics of each autoantibody can coexist. Thus, we should pay attention to the rapidly progressing features of anti-MDA5 as well as the chronic relapsing features of anti-ARS for the better management of this rare condition.